Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

12.51
+0.38003.13%
Post-market: 12.600.0900+0.72%19:58 EST
Volume:3.40M
Turnover:44.13M
Market Cap:274.10M
PE:-0.04
High:14.13
Open:12.00
Low:11.77
Close:12.13
52wk High:65.80
52wk Low:2.62
Shares:21.91M
Float Shares:18.97M
Volume Ratio:0.35
T/O Rate:17.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-342.6591
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-144.27%
PB:-0.12
PE(LYR):-0.37

Loading ...

Vor Biopharma Shares Down 27.9% Premarket After Launching $100 Mln Stock Offering

THOMSON REUTERS
·
Nov 11

BRIEF-Vor Bio Prices Public Offering Of 10 Million Shares At $10 Each

Reuters
·
Nov 11

Vor Biopharma Inc - Prices Public Offering of 10 Mln Shares at $10 Each

THOMSON REUTERS
·
Nov 11

Vor Bio Stock Slides on Public Offering

Dow Jones
·
Nov 11

Vor Biopharma Shares Extend After-Hours Losses; Last Down 27.1%

THOMSON REUTERS
·
Nov 11

BUZZ-Vor Biopharma plunges after $100 mln stock offering launch

Reuters
·
Nov 11

Vor Bio announces $100M common stock offering

TIPRANKS
·
Nov 11

Vor Bio Announces Proposed Public Offering of $100 Million of Common Stock

THOMSON REUTERS
·
Nov 11

Stifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)

TIPRANKS
·
Nov 10

Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept

TIPRANKS
·
Nov 10

BRIEF-Vor Biopharma Says Primary Endpoint Achieved In Phase 3 Clinical Study Evaluating Telitacicept

Reuters
·
Nov 09

Vor Biopharma Inc - Primary Endpoint Achieved in Stage a of a Phase 3 Clinical Study Evaluating Telitacicept in Adults With Iga Nephropathy

THOMSON REUTERS
·
Nov 09

Vor Bio to Participate in 8th Annual Evercore Healthcare Conference

Reuters
·
Nov 07

Vor Bio Appoints Jeremy Sokolove as Chief Medical Officer

Reuters
·
Nov 03

Vor Biopharma Inc expected to post a loss of $3.34 a share - Earnings Preview

Reuters
·
Nov 03

Vor Biopharma Grants Stock Options and RSUs to New Employees Under Inducement Plan

Reuters
·
Nov 01

Major Stock Sale Shakes Up Vor Biopharma!

TIPRANKS
·
Oct 31

Vor Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 30

BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement

Reuters
·
Oct 29

Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study

TIPRANKS
·
Oct 29